First Mature Estimation of Median OS for Selpercatinib in Patients with RET Fusion-Positive NSCLC By Ogkologos - March 12, 2025 631 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from final efficacy and safety analyses from the LIBRETTO-001 study Source RELATED ARTICLESMORE FROM AUTHOR Sacituzumab Govitecan Plus Pembrolizumab Prolongs PFS Among Patients with Previously Untreated, PD-L1-positive, Advanced TNBC FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma MOST POPULAR Occurrence of Interstitial Lung Disease Related to Trastuzumab Deruxtecan in Patients... May 8, 2021 Our 10 top tips to help you talk about cancer April 24, 2023 A Remarkable Group of Patients with Haematological Disorders with No or... December 15, 2021 For People with Inherited Risk of Stomach Cancer, Gastrectomy Has Lasting... January 12, 2024 Load more HOT NEWS EMA Recommends Extension of Indications for Crizotinib A Novel Model Helps Better Predict Risk of Cancer Development in... Metformin May Affect Risk of Breast Cancer in Women with Type... Adding One Year of Palbociclib to Adjuvant Endocrine Treatment Does Not...
